|
WO2009125606A1
|
|
Pai-1 inhibitor
|
|
CN101842093A
|
|
PAI-1 production inhibitor
|
|
EP2208728A1
|
|
Heterocyclic derivative having inhibitory activity on type-i 11 -hydroxysteroid dehydrogenase
|
|
US2010113448A1
|
|
Oxazolidinone derivative having inhibitory activity on 11β-hydroxysteroid dehydrogenase type 1
|
|
WO2008044731A1
|
|
N-phenyloxamidic acid derivative
|
|
EP2080751A1
|
|
Carboxylic acid derivative
|
|
US2008227784A1
|
|
N-(3,4-disubstituted phenyl) salicylamide derivatives
|
|
WO2006095713A1
|
|
Inhibitor of plasminogen activator inhibitor-1
|
|
WO2006036008A1
|
|
Method of displaying molecule function network
|
|
WO2006013873A1
|
|
Drugs having cyclooxygenase inhibiting activity
|
|
WO2005099759A1
|
|
Medicine for prevention and/or treatment of arteriosclerosis
|
|
WO2005094805A1
|
|
Imine derivative and amide derivative
|
|
WO2005026127A1
|
|
Plasminogen activator inhibitor-1 inhibitor
|
|
US2007032996A1
|
|
Molecular function network display method
|
|
WO2004088564A1
|
|
Molecular function network display method
|
|
CN1658854A
|
|
Immunity-related protein kinase inhibitors
|
|
WO03103647A1
|
|
Inhibitors against the activation of ap-1 and nfat
|
|
CN1658850A
|
|
Therapeutic drug for diabetes
|
|
EA009051B1
|
|
O-substituted hydroxyaryl derivatives
|
|
CA2488974A1
|
|
Medicament for treatment of cancer
|
